- by sedlv
- March 21, 2022
By Max Bayer Mar 21, 2022 05:00am
Ever since last year’s annual American Association of Cancer Research (AACR) meeting, Volastra’s phone has been “ringing off the hook,” according to CEO Charles Hugh-Jones, M.D. The interest has now led the oncology biotech to a deal with Bristol Myers Squibb worth up to $1.1 billion, a tantalizing figure for a company still at least a year away from human trials.
One Reply to “Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’”
Thanks for sharing. I read many of your blog posts, cool, your blog is very good. https://accounts.binance.com/sv/register?ref=V2H9AFPY